Despite intensified warnings from regulators about fetal risk associated with the use of valproic acid during pregnancy, pregnancy incidence rates in women receiving valproic acid have remained largely unchanged, results of a cohort study suggest. Use of contraception in this population has also remained low overall, the investigators reported. Study results were published May 22, 2024, in JAMA Network Open .
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: